Management of advanced renal cell carcinoma
10.3760/cma.j.issn.1673-4203.2010.05.013
- VernacularTitle:进展期肾细胞癌的治疗进展
- Author:
Fengbo ZHANG
;
Peiqian YANG
;
Wencheng LV
;
Ye TIAN
- Publication Type:Journal Article
- Keywords:
Kidney;
Renal cell carcinoma;
Targetedtherapy;
Prognosis
- From:
International Journal of Surgery
2010;37(5):328-331
- CountryChina
- Language:Chinese
-
Abstract:
Radiotherapy and chemotherapy have little or no effect on advanced renal cell carcinoma, leading to a poor prognosis. Several factors couLd affect the survival rate of RCC. Some RCC patients could partly respond to immunotherapy.The newly emerging targeted therapy has a dramatic tuning point in improving outcomes for RCC. Further understanding of the anti-RCC mechanisms involves in chemokine-mediated angiogenesis and RCC cell proliferation. These new agents include Sorafenib, Sunitinib, Temsirolimus, Bevacizumab, etc. Combination treatment with immunotherapy may lead to improved outcomes in this disease.
